STEROID HORMONE PHARMACEUTICAL FORMULATIONS

This disclosure provides pharmaceutical compositions for delivering estradiol to a subject in need thereof, as well as methods of administering the compositions, and methods of using them.

Skip to: Description  ·  Claims  · Patent History  ·  Patent History
Description
FIELD

This disclosure provides pharmaceutical compositions comprising solubilized estradiol. Also provided are vaginally inserted soft capsules comprising the pharmaceutical compositions and methods of administering the soft capsules for the treatment of vulvovaginal atrophy and female sexual dysfunction.

BACKGROUND

Postmenopausal women frequently suffer from atrophic vaginitis or vulvar and vaginal atrophy (hereafter “vulvovaginal atrophy” or “VVA”) with symptoms including, for example, vaginal dryness, vaginal odor, vaginal or vulvar irritation or itching, dysuria (pain, burning, or stinging when urinating), dyspareunia (vaginal pain associated with sexual activity), or vaginal bleeding associated with sexual activity. Other symptoms include soreness, urinary frequency and urgency, and urinary discomfort and incontinence (“estrogen-deficient urinary state(s)”). One symptom of vaginal atrophy is an increased vaginal pH, which creates an environment more susceptible to infections. The cytological examination of the vaginal mucosal epithelium in VVA subjects can also show signs of severe atrophy with a reduced number of superficial and intermediate cells an increased number of parabasal cells.

These symptoms are associated with decreased estrogenization of the vulvovaginal tissue and can even occur in women treated with oral estrogen-based pharmaceutical drug products. Although VVA is most common in postmenopausal women, it can occur at any time in a woman's life, and frequently interferes with sexual activity and satisfaction. Postmenopausal women with female sexual dysfunction (FSD) are almost four times more likely to have VVA than those without FSD.

Estrogen treatment has proven to be very successful in controlling menopausal symptoms, including VVA and FSD. Several studies have shown that the symptoms associated with vulvovaginal atrophy are often relieved by systemic or topical estrogen treatment.

SUMMARY

In a first aspect, the present disclosure provides a vaginal insert comprising a therapeutically effective amount of estradiol; and a solubilizing agent, wherein the solubilizing agent comprises at least one C2-C5 fatty acid or a glycol ester, monoglyceride, diglyceride, or triglyceride thereof.

In a first embodiment of the first aspect, the therapeutically effective amount of estradiol is from about 1 microgram to about 25 micrograms. In a second embodiment of the first aspect, the therapeutically effective amount of estradiol is from about 1 microgram to about 10 micrograms. In a third embodiment of the first aspect, the therapeutically effective amount of estradiol is about 4 micrograms. In a fourth embodiment of the first aspect, the therapeutically effective amount of estradiol is about 10 micrograms. In a fifth embodiment of the first aspect, the therapeutically effective amount of estradiol is about 25 micrograms.

In a sixth embodiment of the first aspect, the vaginal insert further comprises a second solubilizing agent selected from the group consisting of a mixture of PEG-6 stearate, ethylene glycol palmitostearate, and PEG-32 stearate; a mixture of hard fat, glyceryl ricinoleate, ceteth-20, and steareth-20; polyoxyl 40 hydrogenated castor oil USP; hard fat polyoxyl 20 cetostearyl ether; and combinations thereof. In a seventh embodiment of the first aspect, the second solubilizing agent is a mixture of PEG-6 stearate, ethylene glycol palmitostearate, and PEG-32 stearate.

In an eighth embodiment of the first aspect, the viscosity of the composition is about 5 cP to about 3000 cP at room temperature.

In a ninth embodiment of the first aspect, estradiol is the only active pharmaceutical ingredient in the vaginal insert.

In a tenth embodiment of the first aspect, the insert further comprises a capsule encapsulating the therapeutically effective amount of estradiol and the solubilizing agent. In an eleventh embodiment of the first aspect, the capsule is a soft gelatin capsule.

In a twelfth embodiment of the first aspect, the solubilizing agent comprises at least one C3 fatty acid or a glycol mono- or di-ester thereof, a monoglyceride, diglyceride, or triglyceride thereof, or a combination of any of the foregoing.

In a second aspect, the present disclosure provides a vaginal insert comprising:

    • a therapeutically effective amount of estradiol;
    • a first solubilizing agent comprising one or more polyethylene glycol mono- or di-esters of a hydroxy C16-C26 fatty acid; and
    • a second solubilizing agent comprising a mixture of PEG-6 stearate, ethylene glycol palmitostearate, and PEG-32 stearate.

In a first embodiment of the second aspect, the therapeutically effective amount of estradiol is from about 1 microgram to about 25 micrograms. In a second embodiment of the second aspect, the therapeutically effective amount of estradiol is from about 1 microgram to about 10 micrograms. In a third embodiment of the second aspect, the therapeutically effective amount of estradiol is about 4 micrograms. In a fourth embodiment of the second aspect, the therapeutically effective amount of estradiol is about 10 micrograms. In a fifth embodiment of the second aspect, the therapeutically effective amount of estradiol is about 25 micrograms.

In a sixth embodiment of the second aspect, estradiol is the only active pharmaceutical ingredient in the vaginal insert.

In a seventh embodiment of the second aspect, the insert further comprises a capsule encapsulating the estradiol, the first solubilizing agent, and the second solubilizing agent. In an eighth embodiment of the second aspect, the capsule is a soft gelatin capsule.

In a third aspect, the present disclosure provides a vaginal insert comprising:

    • a therapeutically effective amount of estradiol;
    • a first solubilizing agent comprising propylene glycol monolaurate; and
    • a second solubilizing agent comprising polyoxyl 40 hydrogenated castor oil USP.

In a first embodiment of the third aspect, the therapeutically effective amount of estradiol is from about 1 microgram to about 25 micrograms. In a second embodiment of the third aspect, the therapeutically effective amount of estradiol is from about 1 microgram to about 10 micrograms. In a third embodiment of the third aspect, the therapeutically effective amount of estradiol is about 4 micrograms. In a fourth embodiment of the third aspect, the therapeutically effective amount of estradiol is about 10 micrograms. In a fifth embodiment of the third aspect, the therapeutically effective amount of estradiol is about 25 micrograms.

In a sixth embodiment of the third aspect, the viscosity of the composition is about 5 cP to about 3000 cP at room temperature.

In a seventh embodiment of the third aspect, estradiol is the only active pharmaceutical ingredient in the vaginal insert.

In an eighth embodiment of the third aspect, the insert further comprises a capsule encapsulating the estradiol, the first solubilizing agent, and the second solubilizing agent. In a ninth embodiment of the third aspect, the capsule is a soft gelatin capsule.

In a fourth aspect, the present disclosure provides a method of treating an estrogen-deficient state, comprising administering to a female in need thereof, a vaginal insert comprising a therapeutically effective amount of estradiol; and a solubilizing agent, wherein the solubilizing agent comprises at least one C2-C5 fatty acid or a glycol ester, monoglyceride, diglyceride, or triglyceride thereof. In a first embodiment of the fourth aspect, the estrogen-deficient state is vulvovaginal atrophy. In a second embodiment of the fourth aspect, the estrogen-deficient state is selected from the group consisting of vulvovaginal atrophy, dysuria, dyspareunia, estrogen-deficient urinary state, and vaginal bleeding associated with sexual activity.

In a third embodiment of the fourth aspect, administering the vaginal insert comprises administering the insert daily for two weeks, and twice weekly thereafter.

In a fifth aspect, the present disclosure provides a method of treating an estrogen-deficient state, comprising administering to a female in need thereof, a vaginal insert comprising:

    • a therapeutically effective amount of estradiol;
    • a first solubilizing agent comprising one or more polyethylene glycol mono- or di-esters of a hydroxy C16-C26 fatty acid; and
    • a second solubilizing agent comprising a mixture of PEG-6 stearate, ethylene glycol palmitostearate, and PEG-32 stearate.

In a first embodiment of the fifth aspect, the estrogen-deficient state is vulvovaginal atrophy. In a second embodiment of the fifth aspect, the estrogen-deficient state is selected from the group consisting of vulvovaginal atrophy, dysuria, dyspareunia, estrogen-deficient urinary state, and vaginal bleeding associated with sexual activity.

In a third embodiment of the fifth aspect, administering the vaginal insert comprises administering the insert daily for two weeks, and twice weekly thereafter.

In a sixth aspect, the present disclosure provides a method of treating an estrogen-deficient state, comprising administering to a female in need thereof, a vaginal insert comprising:

    • a therapeutically effective amount of estradiol;
    • a first solubilizing agent comprising propylene glycol monolaurate; and
    • a second solubilizing agent comprising polyoxyl 40 hydrogenated castor oil USP.

In a first embodiment of the sixth aspect, the estrogen-deficient state is vulvovaginal atrophy. In a second embodiment of the sixth aspect, the estrogen-deficient state is selected from the group consisting of vulvovaginal atrophy, dysuria, dyspareunia, estrogen-deficient urinary state, and vaginal bleeding associated with sexual activity.

In a third embodiment of the sixth aspect, administering the vaginal insert comprises administering the insert daily for two weeks, and twice weekly thereafter.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 depicts a flow diagram illustrating a process for preparing a vaginal insert.

FIG. 2 illustrates a vaginal insert in accordance with various embodiments disclosed herein.

FIG. 3A shows an estradiol softgel capsule held with the larger end between the thumb and index fingers.

FIG. 3B shows insertion of an estradiol softgel capsule in a reclining position. The softgel is inserted into the lower third of the vagina with the smaller end up.

FIG. 3C shows insertion of an estradiol softgel capsule in a standing position. The softgel is inserted into the lower third of the vagina with the smaller end up.

 DETAILED DESCRIPTION Definitions

The singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise.

As used herein, the term “or” is defined as a logical disjunction (i.e., and/or) and does not indicate an exclusive disjunction unless expressly indicated as such with the terms “either,” “unless,” “alternatively,” and words of similar effect.

As used herein, the term “about” refers to ±10% of the noted value, unless otherwise specified, and unless the upper bound of the range would exceed 100% of the pharmaceutical composition, in which case the upper limit of the range is limited to 99.9%. Thus, and by way of example only, a pharmaceutical composition including about 10 weight percent of a given compound could have from 9 to 11 weight percent of the compound. Similarly, a pharmaceutical composition including about 95 weight percent of a given compound could have from 85.5 to 99.9 weight percent of the compound in the pharmaceutical composition.

As used herein, the term “drug product” means at least one active pharmaceutical ingredient in combination with at least one excipient and provided in unit dosage form.

As used herein, the term “hormone deficiency” refers to a low level of one or more steroid hormones in a subject. Normal hormone levels will vary from subject to subject and can be determined via known methods. Low hormone levels may or may not be associated with symptoms including, for example and without limitation, vasomotor symptoms, sleep disturbances, mood changes, and vulvovaginal atrophy.

As used herein, the term “subject” refers to any animal, including humans.

The term “micronized” as used herein, refers to particles having an X50 particle size value below about 15 microns or having an X90 particle size value below about 25 microns. In some embodiments, a micronized particle can have an X90 particle size of less than 5 microns. The term “X50” means that one-half of the particles in a sample are smaller in diameter than a given number. For example, a micronized particle having an X50 of 5 microns means that, for a given sample of the micronized particle, one-half of the particles have a diameter of less than 5 microns. Similarly, the term “X90” means that ninety percent (90%) of the particles in a sample are smaller in diameter than a given number.

As used herein, the term “predominantly” means at least 50 percent. By way of example only, a compound comprising a linear predominantly C10 alkylene group, comprises at least 50 percent, at least 60 percent, at least 70 percent, at least 80 percent, at least 85 percent, at least 90 percent, at least 91 percent, at least 92 percent, at least 93 percent, at least 94 percent, at least 95 percent, at least 96 percent, at least 97 percent, at least 98 percent, or at least 99 percent of the linear C10 alkylene group, with the remainder being an alkylene group either greater than or less than C10. In certain embodiments, predominantly means at least 85 percent. “Predominantly” can be used in a variety of unit measurement systems, including mol %, w/w, or aggregate number of fatty acid esters, for example.

The term “glyceride” is an ester of glycerol (1,2,3-propanetriol) with acyl radicals of fatty acids and is known as an acylglycerol. If only one position of the glycerol molecule is esterified with a fatty acid, a “monoglyceride” or “monoacylglycerol” is produced; if two positions are esterified, a “diglyceride” or “diacylglycerol” is produced; and if all three positions of the glycerol are esterified with fatty acids, a “triglyceride” or “triacylglycerol” is produced. A glyceride is “simple” if all esterified positions contain the same fatty acid; whereas a glyceride is “mixed” if the esterified positions contained different fatty acids. The carbons of the glycerol backbone are designated sn-1, sn-2 and sn-3, with sn-2 being in the middle carbon and sn-1 and sn-3 being the end carbons of the glycerol backbone.

The term “solubilizing agent” refers to an agent or combination of agents that solubilize an active pharmaceutical ingredient (e.g., estradiol). Solubilizing agents include agents that solubilize or dissolve an active pharmaceutical ingredient to a desirable extent. Solubilizing agents suitable for use in the formulations disclosed herein are pharmaceutical grade solubilizing agents. It will be understood by those of skill in the art that other excipients or components can be added to or mixed with the solubilizing agent to enhance the properties or performance of the solubilizing agent or resulting formulation. Examples of such excipients include, but are not limited to, surfactants, emulsifiers, thickeners, colorants, flavoring agents, etc.

As used herein, the term “prevent” refers to the prophylactic treatment of a subject who is at risk of developing a condition (e.g., steroid hormone deficiency) resulting in a decrease in the probability that the subject will develop the condition.

The terms “treat,” “treating,” “treatment” and the like refer to any indicia of success in the treatment or amelioration of an injury, disease, or condition, including any objective or subjective parameter such as abatement; remission; diminishing of symptoms or making the injury, disease, or condition more tolerable to the subject; slowing in the rate of degeneration or decline; or improving a subject's physical or mental well-being. The treatment or amelioration of symptoms can be based on objective or subjective parameters, including the results of a physical examination, neuropsychiatric examinations, or psychiatric evaluation.

The terms “atrophic vaginitis,” “vulvovaginal atrophy,” “vaginal atrophy,” and “VVA” are used herein interchangeably. The cellular morphology of VVA is well known in the medical field.

As used herein, “sexual dysfunction” refers to a condition having one or more symptoms or difficulties involving one or more aspects of sexual activity. The dysfunction can prevent an individual from enjoying sexual activity. Nonlimiting examples of symptoms of sexual dysfunction include, but are not limited to, dyspareunia, painful contractions (spasms) of the vaginal muscles, and problems with sexual desire, arousal, or orgasm. Sexual dysfunction can be lifelong (no effective performance) or acquired (after a period of normal function); and can be generalized or limited to certain situations or certain partners.

As used herein, “dyspareunia” refers to persistent or recurrent genital pain that occurs just before, during, or after sexual activity.

As used herein, “lubrication” refers to wetness in and around the vagina before, during, or after sexual activity. Increasing lubrication can include increasing the frequency of lubrication; decreasing the difficulty of becoming lubricated; and/or decreasing the difficulty in maintaining lubrication.

As used herein, “sexual desire” refers to the frequency of wanting to engage in sexual activity and/or the frequency of engaging in sexual activity as perceived by the individual. Sexual desire can be expressed, for example, in one or more cognitive activities, including the frequency of sexual thoughts, the extent of enjoyment of movies, books, music, etc. having sexual content and/or the extent of enjoyment or pleasure of thinking and fantasizing about sex as perceived by the individual.

As used herein, “sexual arousal” refers to the frequency of becoming sexually aroused, how readily sexual arousal occurs and/or if arousal is maintained, as perceived by the individual. Psychologically, arousal can include factors such as increased desire for sexual activity and excitement related to sexual activity. Physiologically, arousal can include increased blood flow to the genitals, causing clitoral engorgement, as well as vaginal lubrication.

As used herein, “orgasm” refers to the highest point of sexual excitement characterized by a subjective experience of intense pleasure marked normally by vaginal contractions in females. Increasing orgasm can include increasing the frequency, duration, and/or intensity of orgasms in a subject. Increasing orgasm can also include decreasing the difficulty of reaching orgasm.

As used herein, “satisfaction” refers to one or more positive emotions (e.g., contentment, fulfillment, gratification, and the like) related to a sexual activity or sexual relationship. Satisfaction can include, for example, satisfaction with occurrence of sexual arousal or orgasm, satisfaction with the amount of closeness with a partner, and satisfaction with overall sex life.

The phrase “therapeutically effective amount” refers to an amount of a pharmaceutical composition or of a given steroid hormone suitable to treat a particular symptom, disorder, or disease.

As used herein, the phrase “substantially” means at least about 90%, in certain embodiments, at least about 95%, and in still further embodiments, at least about 98%. For example, an object that is “substantially pure” or an object that is “substantially free” of another object, refers to a compound or composition that is at least about 90% pure by weight, at least about 95% pure by weight, or at least about 98% pure by weight and contains less than about 10% by weight, less than about 5% by weight or less than about 2% by weight of contaminants.

As used herein, the phrase “steroid hormone” refers to estradiol.

The term “bio-identical,” “body-identical,” or “natural” used in conjunction with the hormones disclosed herein, means hormones that match the chemical structure and effect of those that occur naturally or endogenously in the human body. An exemplary natural estrogen is 17β-estradiol.

The term “estradiol” refers to (17β)-estra-1,3,5(10)-triene-3,17-diol. Estradiol is also interchangeably called 17β-estradiol, oestradiol, or E2, and is found endogenously in the human body. As used herein, estradiol refers to the bio-identical or body-identical form of estradiol found in the human body having the structure:

Estradiol is supplied in an anhydrous or hemi-hydrate form. For the purposes of this disclosure, the anhydrous form or the hemihydrate form can be substituted for the other by accounting for the water or lack of water according to well-known and understood techniques.

The term “solubilized estradiol” means that the estradiol or a portion thereof is solubilized or dissolved in the solubilizing agent(s) or the formulations disclosed herein. Solubilized estradiol can include estradiol that is about 80% solubilized, about 85% solubilized, about 90% solubilized, about 95% solubilized, about 96% solubilized, about 97% solubilized, about 98% solubilized, about 99% solubilized, or about 100% solubilized. In some embodiments, the estradiol is “fully solubilized” with all or substantially all of the estradiol being solubilized or dissolved in the solubilizing agent. Fully solubilized estradiol can include estradiol that is about 97% solubilized, about 98% solubilized, about 99% solubilized or 100% solubilized. Solubility can be expressed as a mass fraction (% w/w, which is also referred to as weight percent (wt %)).

The solubility of a given steroid hormone can be measured using standard techniques by weighing a piece of filter paper, placing the weighed filter paper in a Buchner funnel (porcelain or glass with a glass frit), and drawing a known quantity of pharmaceutical composition through the filter paper using vacuum (such as with a side-arm flask fitted with a neoprene collar). After drying for an appropriate period of time (either at room temperature or at elevated temperature), the filter paper is reweighed. The amount of steroid hormone on the filter paper is calculated and the amount of soluble and insoluble steroid hormone is calculated.

The term “excipients,” as used herein, refers to non-API ingredients such as solubilizing agents, anti-oxidants, oils, lubricants, and other agents used in formulating pharmaceutical products.

The term “active pharmaceutical ingredient” (“API”) as used herein, means the active compound(s) used in formulating a drug product.

Pharmaceutical Compositions

Provided herein are pharmaceutical compositions comprising estradiol designed to be absorbed vaginally and have a local therapeutic effect (e.g., in vaginal and vulvar tissues). Generally, the pharmaceutical compositions disclosed herein are useful for treating VVA, dyspareunia, and other disorders caused by decreased estrogen presence.

Functionality

In certain embodiments, the pharmaceutical compositions disclosed herein can be alcohol-free or substantially alcohol-free. In certain embodiments, the pharmaceutical compositions disclosed herein can be encapsulated in soft gelatin capsules.

Estradiol

In certain embodiments, the pharmaceutical compositions disclosed herein are for vaginal insertion through a single dose or through multiple doses. In certain embodiments, the estradiol in the pharmaceutical compositions can be 100% solubilized. In certain embodiments, the estradiol in the pharmaceutical compositions can be less than 100% solubilized. In embodiments where the estradiol is less than 100% solubilized, the remaining estradiol can be present in a micronized (crystalline) form that is absorbable by the body and retains biological functionality, either in its micronized form or in another form which the micronized form is converted to after administration.

In certain embodiments, all or some of the estradiol can be solubilized in one or more solubilizing agents during manufacturing process. In certain embodiments, all or some of the estradiol can be solubilized following administration (e.g., insoluble estradiol in the formulation can be solubilized in a body fluid after administration). To the extent the estradiol is not fully solubilized at the time of administration/insertion, the estradiol will be substantially solubilized at a body temperature (average of 37° C.) and, generally, at the pH of the vagina (ranges from 3.8 to 4.5 in healthy subjects; or 4.6 to 6.5 in VVA subjects).

In certain embodiments, estradiol can be soluble in the solubilizing agent(s) at room temperature, although it can be desirable to warm certain solubilizing agents during manufacture to improve viscosity. In certain embodiments, the solubilizing agent can be a liquid or semi-solid. In certain embodiments, the solubilizing agent can be a liquid at between room temperature and about 50° C., at or below 50° C., at or below 40° C., or at or below 30° C.

In certain embodiments, the viscosity of the pharmaceutical compositions described this disclosure can range from about 5 centipose (“cP”) to about 3000 cP at 25° C. A person of ordinary skill in the art can readily understand and select from suitable solubilizing agents to arrive at the desired viscosity. Viscosity can be measured by various types of viscosity meters and rheometers. These instruments measure the friction between the fluid and an adjacent layer. For example, a Brookfield Viscometer (DVEELVTJ0) can be used to measure the viscosity of these compositions by using an S31 spindle at 5-100 rpm and at room temperature.

In certain embodiments, the viscosity of the pharmaceutical compositions described in this disclosure will exceed 3000 cP, e.g., for semi-solids or solids. A person of ordinary skill in the art can readily measure the viscosity of such semi-solids or solids by using other known methods, e.g., increasing temperature or using different spindles.

In certain embodiments, the solubility of estradiol in the solubilizing agent(s) can be about 0.01 wt %, 0.02 wt %, 0.05 wt %, 0.06 wt %, 0.08 wt %, 0.1 wt %, 0.2 wt %, 0.3 wt %, 0.4 wt %, 0.5 wt %, 0.6 wt %, 0.7 wt %, 0.8 wt %, 0.9 wt %, 1.0 wt %, or higher. In some embodiments, the solubility of estradiol in the solubilizing agent(s) can be from about 0.001 wt % to about 5 wt %, from about 0.001 wt % to about 2 wt %, from about 0.001 wt % to about 1 wt %, from about 0.001 wt % to about 0.5 wt %, from about 0.001 wt % to about 0.1 wt %, from about 0.001 wt % to about 0.05 wt %, from about 0.01 wt % to about 5 wt %, from about 0.01 wt % to about 2 wt %, from about 0.01 wt % to about 1 wt %, from about 0.01 wt % to about 0.5 wt %, from about 0.01 wt % to about 0.1 wt %, from about 0.1 wt % to about 5 wt %, from about 0.1 wt % to about 2 wt %, from about 0.1 wt % to about 1 wt %, from about 0.1 wt % to about 0.5 wt %, from about 0.5 wt % to about 5 wt %, from about 0.5 wt % to about 2 wt %, from about 0.5 wt % to about 1 wt %, from about 1 wt % to about 5 wt %, from about 1 wt % to about 2 wt %, or from about 2 wt % to about 5 wt %.

In certain embodiments, the estradiol can be added to the pharmaceutical compositions disclosed herein as estradiol, estradiol hemihydrate, or any other estradiol form(s) suitable for use in pharmaceutical compositions or formulations.

The pharmaceutical compositions described herein can contain estradiol in varying amounts. Estradiol (or estradiol hemihydrate, for example, to the extent the water content of the estradiol hemihydrate is accounted for) can be present in the formulation in a dosage amount ranging from about 1 microgram (m) to about 50 μg. In other embodiments, the pharmaceutical composition can contain about: 1 μg, 2 μg, 3 μg, 4 μg, 5 μg, 6 μg, 7 μg, 8 μg, 9 μg, 10 μg, 11 μg, 12 μg, 13 μg, 14 μg, 15 μg, 16 μg, 17 μg, 18 μg, 19 μg, 20 μg, 21 μg, 22 μg, 23 μg, 24 μg, 25 μg, 26 μg, 27 μg, 28 μg, 29 μg, 30 μg, 31 μg, 32 μg, 33 μg, 34 μg, 35 μg, 36 μg, 37 μg, 38 μg, 39 μg, 40 μg, 41 μg, 42 μg, 43 μg, 44 μg, 45 μg, 46 μg, 47 μg, 48 μg, 49 μg, or 50 μg estradiol (or an equivalent amount of, for example, estradiol hemihydrate). In certain embodiments, the pharmaceutical composition can contain about 2.5 μg, 4 μg, 6.25 μg, 7.5 μg, 12.5 μg, or 18.75 μg of estradiol. In certain embodiments, the pharmaceutical composition can contain from about 1 μg to about 10 from about 3 μg to about 7 μg, from about 7.5 μg to 12.5 μg, from about 10 μg to about 25 μg, from about 1 μg, about 2.5 μg, from about 23.5 μg to about 27.5 μg, from about 7.5 μg to about 22.5 μg, or from about 10 μg to about 25 μg of estradiol. In one embodiment, the pharmaceutical composition comprises about 4 μg of estradiol. In one embodiment, the pharmaceutical composition comprises about 10 μg of estradiol. In another embodiment, the pharmaceutical composition comprises about 25 μg of estradiol.

In some embodiments, estradiol is the only active hormone in the vaginally inserted pharmaceutical composition.

Short Chain (C2-C5) Fatty Acids as Solubilizing Agents

In certain embodiments, the solubilizing agent can comprise at least one short chain fatty acid (C2-C5). In some embodiments, the short chain fatty acid can be acetic acid (C2), propionic acid (C3), butyric acid (C4), isobutyric acid (C4), valeric acid (C5), isovaleric acid (C5), or mixtures thereof.

In embodiments where the solubilizing agent comprises one or more C3-C5 short chain fatty acids, the one or more C3-C5 fatty acids can be saturated. In certain embodiments, the one or more C3-C5 short chain fatty acids can be predominantly saturated, i.e., greater than about 60% or greater than about 75% saturated.

In certain embodiments, the solubilizing agent can comprise one or more free short chain fatty acids, one or more short chain fatty acid (C2-C5) esters of glycerin, propylene glycol, ethylene glycol, or combinations thereof. Exemplary short chain fatty acid (C2-C5) esters of glycerin include, but are not limited to, monoacetylglyceride (MAG), diacetylglyceride (DAG), triacetin (triacetylglyceride, TAG), propionic triglyceride, monobutylglyceride, dibutylglyceride, butyric triglyceride (tributyrin), isobutyric triglyceride, isobutyric diglyceride, isobutyric monoglyceride, valeric triglyceride, valeric diglyceride, valeric monoglyceride, isovaleric monoglyceride, isovaleric diglyceride and isovaleric triglyceride. In some embodiments, the solubilizing agent can comprise triacetin.

In certain embodiments, the pharmaceutical composition can comprise a first solubilizing agent comprising at least one C2-C5 fatty acid or a glycol ester, monoglyceride, diglyceride, or triglyceride thereof and a second solubilizing agent. The second solubilizing agent can be any agent that solubilizes or dissolves the steroid hormone to the desirable extent.

In some embodiments, the second solubilizing agent can be TEFOSE 63 (mixture of PEG-6 stearate and ethylene glycol palmitostearate and PEG-32 stearate, available from GATTEFOSSÉ SAS, Saint-Priest, France), TEFOSE 1500 (mixture of PEG-6 stearate and PEG-32 stearate, available from GATTEFOSSÉ SAS, Saint-Priest, France), TEFOSE 2000 (mixture of PEG-6 stearate, ceteth-20, and stearath-20, available from GATTEFOSSÉ SAS, Saint-Priest, France), or GELOT 64 (mixture of PEG-75 stearate and glyceryl stearate, available from GATTEFOSSÉ SAS, Saint-Priest, France).

In certain embodiments, the second solubilizing agent can comprise one or more C6-C18 fatty acid PEG mono- or di-esters, one or more C6-C18 fatty acid mono-, di-, or tri-esters of glycerol, or combinations thereof. In one embodiment, the second solubilizing agent can be GELUCIRE 44/14 (lauroyl macrogol-32 glycerides (EP); lauroyl polyoxyl-32 glycerides (USP-NF)). Gelucire 44/14 is well known in the art and comprises a small fraction of mono-, di-, and triglycerides and a main fraction comprising PEG-32 (MW 1500) mono- and diesters of lauric acid (C12).

In certain embodiments, the second solubilizing agent can comprise a castor oil or hydrogenated castor oil ethoxylate. In particular embodiments, the castor oil or hydrogenated castor oil ethoxylate can be KOLLIPHOR EL (polyethoxylated castor oil, available from BASF), KOLLIPHOR RH40 (polyoxyl 40 hydrogenated castor oil USP, available from BASF), MYRJ 52 (polyoxyl 40 stearate, available from Spectrum Chemical), ETOCAS 40 (polyoxyethylene (40) castor oil, available from Croda), LABRASOL (caprylocaproyl polyoxyl-8-glycerides NF and caprylocaproyl macrogol-8-glycerides EP, available from GATTEFOSSÉ SAS, Saint-Priest, France), or CRODURET 60 (PEG 60 hydrogenated castor oil, available from Croda).

In certain embodiments, the second solubilizer can comprise OVUCIRE 3460 (a mixture of hard fat, glyceryl ricinoleate, ceteth-20, and steareth-20, available from GATTEFOSSÉ, Saint-Priest, France) or OVUCIRE WL 3264 (hard fat polyoxyl 20 cetostearyl ether, available from GATTEFOSSÉ, Saint-Priest, France).

In some embodiments, the weight:weight ratio of the first solubilizing agent to the second solubilizing agent can range from about 4:1 to about 10:1. In particular embodiments, the ratio of first solubilizing agent to second solubilizing agent is about 9:1.

In some embodiments, the pharmaceutical composition can comprise a first solubilizing agent comprising at least one C2-C5 fatty acid or a glycol ester, monoglyceride, diglyceride, or triglyceride thereof, and a second solubilizing agent comprising a mixture polyoxylglycerides and glycols. In particular embodiments, the pharmaceutical composition can comprise a 9:1 mixture of triacetin and TEFOSE 63 (mixture of PEG-6 stearate and ethylene glycol palmitostearate and PEG-32 stearate, available from GATTEFOSSÉ SAS, Saint-Priest, France).

Hydroxy Fatty Acids as Solubilizing Agents

In certain embodiments, the solubilizing agent can comprise at least one hydroxy fatty acid, such as at least one hydroxy C16-C26 fatty acid, at least one hydroxy C16 to C24 fatty acid, at least one hydroxy C16 to C22 fatty acid, at least one hydroxy C16 to C20, at least one hydroxy C16 to C18 fatty acid, at least one hydroxy C18 to C26 fatty acid, at least one hydroxy C18 to C24 fatty acid, at least one hydroxy C18 to C22 fatty acid, at least one hydroxy C18 to C20 fatty acid, or a combination thereof.

In some embodiments, the various suitable hydroxy fatty acids noted above can be saturated. In some embodiments, these hydroxy fatty acids can be predominantly saturated, i.e., greater than about 60% or greater than about 75% saturated.

In certain embodiments, the hydoxy fatty acid can be a C16-C26 hydoxy fatty acid and can be α-hydroxymyristic acid, β-hydroxymyristic acid, 3-hydroxy-13-methyltetradecanoic acid, α-hydroxypalmitic acid, β-hydroxypalmitic acid, 3-hydroxy-15-methylhexadecanoic acid, β-hydroxystearic acid, 12-hydroxystearic acid, and 17-hydroxystearic acid, or a mixture of any of the foregoing.

In certain embodiments, the solubilizing agent can comprise one or more glycol mono- or di-esters of a hydroxy C16-C26 fatty acid. Suitable glycols can include ethylene glycol, propylene glycol, and polyethylene glycol. In some embodiments, the solubilizing agent can comprise one or more polyethylene glycol mono- or di-esters of a hydroxy C16-C26 fatty acid. In some embodiments, the solubilizing agent can comprise one or more polyethylene glycol mono- or di-esters of a C16-C26 fatty acid. In some embodiments, the solubilizing agent comprises a mixture of one or more polyethylene glycol mono- and di-esters of a hydroxy C16-C26 fatty acid and one or more polyethylene glycol di-esters of a C16-C26 fatty acid. In some embodiments, the solubilizing agent comprises polyethylene glycol mono- and di-esters of 12-hydroxystearic acid and free polyethylene glycol (sold as KOLLIPHOR HS 15, available from BASF).

In certain embodiments, the pharmaceutical composition can comprise a first solubilizing agent comprising one or more polyethylene glycol mono-esters of a C6-C26 hydroxyfatty acid, one or more polyethylene glycol di-esters of a C6-C26 hydroxyfatty acid, or a combination thereof; and a second solubilizing agent.

In some embodiments, the second solubilizing agent can be TEFOSE 63 (mixture of PEG-6 stearate and ethylene glycol palmitostearate and PEG-32 stearate, available from GATTEFOSSÉ SAS, Saint-Priest, France), TEFOSE 1500 (mixture of PEG-6 stearate and PEG-32 stearate, available from GATTEFOSSÉ SAS, Saint-Priest, France), TEFOSE 2000 (mixture of PEG-6 stearate, ceteth-20, and stearath-20, available from GATTEFOSSÉ SAS, Saint-Priest, France), or GELOT 64 (mixture of PEG-75 stearate and glyceryl stearate, available from GATTEFOSSÉ SAS, Saint-Priest, France).

In certain embodiments, the second solubilizing agent can comprise one or more C6-C18 fatty acid PEG mono- or di-esters, one or more C6-C18 fatty acid mono-, di-, or tri-esters of glycerol, and combinations thereof. In one embodiment, the second solubilizing agent can be GELUCIRE 44/14.

In certain embodiments, the second solubilizing agent can comprise a castor oil or hydrogenated castor oil ethoxylate. In particular embodiments, the castor oil or hydrogenated castor oil ethoxylate can be KOLLIPHOR EL (polyethoxylated castor oil, available from BASF), KOLLIPHOR RH40 (polyoxyl 40 hydrogenated castor oil USP, available from BASF), MYRJ 52 (polyoxyl 40 stearate, available from Spectrum Chemical), ETOCAS 40 (polyoxyethylene (40) castor oil, available from Croda), LABRASOL (caprylocaproyl polyoxyl-8-glycerides NF and caprylocaproyl macrogol-8-glycerides EP, available from GATTEFOSSÉ SAS, Saint-Priest, France), or CRODURET 60 (PEG 60 hydrogenated castor oil, available from Croda).

In certain embodiments, the second solubilizer can comprise OVUCIRE 3460 (a mixture of hard fat, glyceryl ricinoleate, ceteth-20, and steareth-20, available from GATTEFOSSÉ, Saint-Priest, France) or OVUCIRE WL 3264 (hard fat polyoxyl 20 cetostearyl ether, available from GATTEFOSSÉ, Saint-Priest, France).

In some embodiments, the weight:weight ratio of the first solubilizing agent to the second solubilizing agent can range from 4:1 to about 10:1. In particular embodiments, the ratio of first solubilizing agent to second solubilizing agent can be about 9:1.

In some embodiments, the pharmaceutical composition can comprise a first solubilizing agent comprising one or more PEG esters of a C6-C26 hydroxy fatty acid, one or more PEG diesters of a C6-C26 hydroxy fatty acid, or a combination thereof; and a second solubilizing agent comprising a mixture polyoxylglycerides and glycols. In particular embodiments, the pharmaceutical composition can comprise a 9:1 (w:w) mixture of KOLLIPHOR HS 15 (polyethylene glycol mono- and di-esters of 12-hydroxystearic acid and free polyethylene glycol, available from BASF) and TEFOSE 63 (mixture of PEG-6 stearate and ethylene glycol palmitostearate and PEG-32 stearate, available from GATTEFOSSÉ SAS, Saint-Priest, France).

Propylene Glycol Monolaurate as a Solubilizing Agent

In certain embodiments, the solubilizing agent can comprise propylene glycol monolaurate (sold as LAUROGLYCOL 90, available from GATTEFOSSÉ SAS, Saint-Priest, France).

In some embodiments, the pharmaceutical composition can comprise propylene glycol monolaurate (sold as LAUROGLYCOL 90, available from GATTEFOSSÉ SAS, Saint-Priest, France) and a second solubilizing agent.

In some embodiments, the second solubilizing agent can be TEFOSE 63 (mixture of PEG-6 stearate and ethylene glycol palmitostearate and PEG-32 stearate, available from GATTEFOSSÉ SAS, Saint-Priest, France), TEFOSE 1500 (mixture of PEG-6 stearate and PEG-32 stearate, available from GATTEFOSSÉ SAS, Saint-Priest, France), TEFOSE 2000 (mixture of PEG-6 stearate, ceteth-20, and stearath-20, available from GATTEFOSSÉ SAS, Saint-Priest, France), or GELOT 64 (mixture of PEG-75 stearate and glyceryl stearate, available from GATTEFOSSÉ SAS, Saint-Priest, France).

In certain embodiments, the second solubilizing agent can comprise one or more C6-C18 fatty acid PEG mono- or di-esters, one or more C6-C18 fatty acid mono-, di-, or tri-esters of glycerol, and combinations thereof. In one embodiment, the second solubilizing agent can be GELUCIRE 44/14.

In certain embodiments, the second solubilizing agent can comprise a castor oil or hydrogenated castor oil ethoxylate. In particular embodiments, the castor oil or hydrogenated castor oil ethoxylate can be KOLLIPHOR EL (polyethoxylated castor oil, available from BASF), KOLLIPHOR RH40 (polyoxyl 40 hydrogenated castor oil USP, available from BASF), MYRJ 52 (polyoxyl 40 stearate, available from Spectrum Chemical), ETOCAS 40 (polyoxyethylene (40) castor oil, available from Croda), LABRASOL (caprylocaproyl polyoxyl-8-glycerides NF and caprylocaproyl macrogol-8-glycerides EP, available from GATTEFOSSÉ SAS, Saint-Priest, France), or CRODURET 60 (PEG 60 hydrogenated castor oil, available from Croda).

In certain embodiments, the second solubilizer can comprise OVUCIRE 3460 (a mixture of hard fat, glyceryl ricinoleate, ceteth-20, and steareth-20, available from GATTEFOSSÉ, Saint-Priest, France) or OVUCIRE WL 3264 (hard fat polyoxyl 20 cetostearyl ether, available from GATTEFOSSÉ, Saint-Priest, France).

In some embodiments, the weight:weight ratio of the first solubilizing agent to the second solubilizing agent can be from 4:1 to about 10:1. In particular embodiments, the ratio of first solubilizing agent to second solubilizing agent can be about 9:1 (w:w).

In some embodiments, the pharmaceutical composition can comprise propylene glycol monolaurate (sold as LAUROGLYCOL 90, available from GATTEFOSSÉ SAS, Saint-Priest, France) and a second solubilizing agent comprising polyoxyl 40 hydrogenated castor oil (sold as KOLLIPHOR RH40, available from BASF). In particular embodiments, the pharmaceutical composition can comprise a 9:1 mixture of LAUROGLYCOL 90 and KOLLIPHOR RH40

Methods of Treating Hormone Deficiencies

In addition to the compositions described above, this disclosure further provides methods for treating one or more conditions associated with hormone deficiency in a subject. The methods comprise vaginally administering to a subject in need thereof an effective amount of the pharmaceutical composition described herein.

In some embodiments, the condition being treated can be an estrogen deficiency in the vulvovaginal area, including conditions such as VVA.

In certain embodiments, the pharmaceutical composition can be administered once daily within in any of the above noted amounts until the disease or condition is treated.

In some embodiments, the method of treating the symptoms of VVA comprises administering a vaginal insert comprising the pharmaceutical composition described herein to the vagina of a subject in need thereof, wherein administering the vaginal insert does not require use of an applicator.

In some embodiments, the method of treating the symptoms of VVA comprises administering a vaginal insert comprising the pharmaceutical composition described herein to the vagina of a subject in need thereof, wherein administering the vaginal insert is by digital insertion.

In some embodiments, the method of treating the symptoms of VVA comprises administering a vaginal insert comprising the pharmaceutical composition described herein to the vagina of a subject in need thereof, wherein administering the vaginal insert is by insertion using an applicator.

In some embodiments, the method of treating the symptoms of VVA comprises administering a vaginal insert comprising the pharmaceutical composition described herein to the vagina of a subject in need thereof, wherein the vaginal insert is inserted about two inches into the vagina.

In some embodiments, the method of treating the symptoms of VVA comprises administering a vaginal insert comprising the pharmaceutical composition described herein to the vagina of a subject in need thereof, wherein administering the vaginal insert results in no or minimal subject irritation.

In some embodiments, the method of treating the symptoms of VVA comprises administering a vaginal insert comprising the pharmaceutical composition described herein to the vagina of a subject in need thereof, wherein subject irritation is selected from the group consisting of pain, itching, soreness, excessive discharge, swelling, or combinations thereof.

In some embodiments, the method of treating the symptoms of VVA comprises administering a vaginal insert comprising the pharmaceutical composition described herein to the vagina of a subject in need thereof, wherein subject irritation associated with administering the vaginal insert containing the API does not differ significantly from subject irritation associated with administering a placebo insert.

In some embodiments, the method of treating the symptoms of VVA comprises administering a vaginal insert comprising the pharmaceutical composition described herein to the vagina of a subject in need thereof, wherein subject irritation associated with administering the vaginal insert is reduced compared to subject irritation associated with administering other hormone replacement vaginal inserts.

In some embodiments, the method of treating the symptoms of VVA comprises administering a vaginal insert comprising the pharmaceutical composition described herein to the vagina of a subject in need thereof, wherein after two weeks of administration, the frequency of administering the vaginal insert is less frequent than that required by other hormone replacement vaginal inserts.

In some embodiments, the method of treating the symptoms of VVA comprises administering a vaginal insert comprising the pharmaceutical composition described herein to the vagina of a subject in need thereof, wherein time to ambulation for a subject is less than 20 minutes after administering the vaginal insert.

In some embodiments, the method of treating the symptoms of VVA comprises administering a vaginal insert comprising the pharmaceutical composition described herein to the vagina of a subject in need thereof, wherein time to ambulation for a subject is less than 10 minutes after administering the vaginal insert.

In some embodiments, the method of treating the symptoms of VVA comprises administering a vaginal insert comprising the pharmaceutical composition described herein to the vagina of a subject in need thereof, wherein time to ambulation for a subject is less than 5 minutes after administering the vaginal insert.

In some embodiments, the method of treating the symptoms of VVA comprises administering a vaginal insert comprising the pharmaceutical composition described herein to the vagina of a subject in need thereof, wherein time to ambulation for a subject after administering the vaginal insert is reduced compared to time to ambulation associated with administering other hormone replacement vaginal inserts.

In some embodiments, the method of treating the symptoms of VVA comprises administering a vaginal insert comprising the pharmaceutical composition described herein to the vagina of a subject in need thereof, wherein the vaginal insert can be administered when substantially no vaginal fluid is present in the vagina.

In some embodiments, the method of treating the symptoms of VVA comprises administering a vaginal insert comprising the pharmaceutical composition described herein to the vagina of a subject in need thereof, wherein the vaginal insert further comprises a capsule.

In some embodiments, the method of treating the symptoms of VVA comprises administering a vaginal insert comprising the pharmaceutical composition described herein to the vagina of a subject in need thereof, wherein the vaginal insert further comprises a capsule, wherein the capsule is substantially dissolved in the vagina. In some embodiments, at least about 90% of the capsule is dissolved in the vagina.

In some embodiments, the method of treating the symptoms of VVA comprises administering a vaginal insert comprising the pharmaceutical composition described herein to the vagina of a subject in need thereof, wherein the vaginal insert further comprises a capsule, wherein there is substantially no discharge of contents of the vaginal insert observed within 30 minutes after administering the vaginal insert.

In some embodiments, the method of treating the symptoms of VVA comprises administering a vaginal insert comprising the pharmaceutical composition described herein to the vagina of a subject in need thereof, wherein the vaginal insert further comprises a capsule, wherein there is substantially no discharge of contents of the vaginal insert observed within 2 hours after administering the vaginal insert.

In some embodiments, the method of treating the symptoms of VVA comprises administering a vaginal insert comprising the pharmaceutical composition described herein to the vagina of a subject in need thereof, wherein the vaginal insert further comprises a capsule, wherein the amount of discharge of contents of the vaginal insert is less than the amount of discharge observed with other hormone replacement vaginal inserts, as observed by visual examination.

Also provided is a method for enhancing subject compliance in a population of subjects having symptoms of VVA, comprising administering a vaginal insert comprising the pharmaceutical composition described herein, wherein the pharmaceutical composition comprises 1 microgram to 25 micrograms of estradiol, to the vagina of a subject in need thereof, wherein the subject administers the vaginal insert at least daily for two weeks.

In some embodiments, the present disclosure provides a method for enhancing subject compliance in a population of subjects having symptoms of VVA, the method comprising administering a vaginal insert comprising the pharmaceutical composition described herein to the vagina of a subject in need thereof, wherein the subject administers the vaginal insert daily for two weeks, and at least twice weekly thereafter.

In some embodiments, the present disclosure provides a method for enhancing subject compliance in a population of subjects having symptoms of VVA, the method comprising administering a vaginal insert comprising the pharmaceutical composition described herein to the vagina of a subject in need thereof, wherein compliance of subjects in the population administering the vaginal insert is enhanced compared to compliance of subjects in a population administering other hormone replacement vaginal inserts.

In certain embodiments, the present disclosure provides a method for estrogenizing the vulva, which consists of the labia majora, the labia minora (labia majora and minora are collectively referred to as “the labia”), clitoris, vestibule of the vagina, bulb of the vestibule, and the glands of Bartholin (all of which can come into contact with the liquid that partially flows from the vagina). In some embodiments, an estradiol containing pharmaceutical composition can be digitally inserted about two inches into the vagina or inserted into the third of the vagina closest to the vaginal opening as shown in FIGS. 3A, 3B, and 3C. Without wishing to be bound to a particular theory, it is believed that the estradiol containing pharmaceutical composition dissolves, ruptures, or otherwise releases the pharmaceutical composition into the vagina, whereby the lower third of the vagina and labia are both reestrogenized. In some embodiments, the pharmaceutical composition is a liquid that partially flows to the labia and directly reestrogenizes the labia.

In certain embodiments, the present disclosure provides a method for avoiding transport of the estradiol to the uterus comprising administering an estradiol containing composition into the lower third of the vagina closest to the vaginal opening as shown in FIGS. 3A, 3B, and 3C. Without wishing to be bound by a particular theory, it is believed that the estradiol containing composition releases the estradiol in the lower third of the vagina, which substantially eliminates transport of the estradiol to the uterus, where unopposed estradiol can cause endometrial hyperplasia, which could potentially lead to endometrial cancer.

In certain embodiments, the present disclosure provides a method for estrogenizing the vulva. In some embodiments, the pharmaceutical composition is digitally inserted about two inches into the vagina or inserted into the third of the vagina closest to the vaginal opening as shown in FIGS. 3A, 3B, and 3C. Without wishing to be bound to a particular theory, it is believed that the gelatin capsule containing the pharmaceutical composition dissolves, ruptures, or otherwise releases the pharmaceutical composition into the vagina, whereby the lower third of the vagina and vulva are both reestrogenized. In some embodiments, the pharmaceutical composition can be a liquid that partially flows to the vulval tissue and directly reestrogenizes the vulva.

In certain embodiments, the present disclosure provides a method for treating VVA, including dyspareunia, vaginal dryness, and estrogen-deficient urinary states (including urinary tract infections), wherein a delivery vehicle comprising the pharmaceutical composition for treating VVA is digitally inserted approximately two inches into the vagina or into the third of the vagina closest to the opening of the vagina. This method can result in at least one of: improved compliance compared to other products for the treatment of VVA; improved user experience compared to other products for the treatment of VVA; and statistically significantly improved symptoms of VVA, compared to placebo or baseline within at least one, two, four, six, eight, ten, twelve, or more weeks after initiating administration. In certain embodiments, a method for the treatment of VVA, including dyspareunia, vaginal dryness, and estrogen-deficient urinary states (including urinary tract infections), is provided wherein a delivery vehicle containing a composition for the treatment of VVA in a tear drop shaped capsule as disclosed herein is inserted approximately two inches into the vagina or into the third of the vagina closest to the opening of the vagina. This method can result in at least one of: improved compliance compared to other products for the treatment of VVA; improved user experience compared to other products for the treatment of VVA; and statistically significantly improved symptoms of VVA, compared to placebo or baseline within at least one, two, four, six, eight, ten, twelve, or more weeks after initiation of administration.

Methods for Preparing the Pharmaceutical Compositions

In certain embodiments, the pharmaceutical composition can be prepared by blending estradiol with at least one pharmaceutically acceptable solubilizing agent. In certain embodiments, other excipients including, for example and without limitation, nontoxic pharmaceutically acceptable solvents, co-solvents, surfactants, lubricants, antioxidants, and/or other excipients suitable for vaginal delivery or absorption, and the like can be added to the pharmaceutical composition. In certain embodiments, the pharmaceutical composition can include sufficient solubilizing agent to fully solubilize the estradiol. It is expressly understood, however, the other volumes of solubilizing agent can be used depending on the level of estradiol solubilization desired. Persons of ordinary skill in the art will know and understand how to determine the volume of solubilizing agent and other excipients depending on the desired percent of estradiol to be solubilized in the pharmaceutical composition. In some embodiments, the solubilizing agent can be heated (for example, from about 40° C. to about 65° C.), although such heating is not necessary to dissolve the estradiol.

Delivery Vehicle

Generally, the pharmaceutical compositions described herein are delivered intravaginally inside of a delivery vehicle, for example a capsule. In certain embodiments, the capsules are soft capsules made of materials well-known in the pharmaceutical arts, for example, gelatin. However, in some embodiments, the delivery vehicle is integral with the pharmaceutical composition (i.e., the pharmaceutical composition is the delivery vehicle). In such embodiments the pharmaceutical compositions can be an insert, a gel, a cream, an ointment, a tablet, a suppository, or another preparation that is directly applied and absorbed vaginally.

In certain embodiments, the capsules do not contain one or more of the following: a hydrophilic gel-forming bioadhesive agent, a lipophilic agent, a gelling agent for the lipophilic agent, and/or a hydrodispersible agent. In certain embodiments, the capsules do not contain a hydrophilic gel-forming bioadhesive agent selected from: carboxyvinylic acid, hydroxypropylcellulose, carboxymethylcellulose, gelatin, xanthan gum, guar gum, aluminum silicate, and mixtures thereof. In certain embodiments, the capsules do not contain a lipophilic agent selected from: a liquid triglyceride, a solid triglyceride (with a melting point of about 35° C.), carnauba wax, cocoa butter, or mixtures thereof. In certain embodiments, the capsules do not contain a hydrophobic colloidal silica gelling agent. In certain embodiments, the capsules do not contain a hydrodispersible agent selected from: polyoxyethylene glycol, polyoxyethylene glycol 7-glyceryl-cocoate, or mixtures thereof. In some such embodiments, the liquid composition can be contained with a gelatin capsule as described herein. In some such embodiments, the capsule can comprise gelatin and optionally one or more further components selected from the group consisting of gelatin, hydrolyzed gelatin, sorbitol-sorbitan solution, water, glycerin, titanium dioxide, FD&C Red #40, ethanol, ethyl acetate, propylene glycol, polyvinyl acetate phthalate, isopropyl alcohol, polyethylene glycol, and ammonium hydroxide.

In certain embodiments, the delivery vehicle can be designed for ease of insertion. In certain embodiments, the delivery vehicle can be sized so that it can be comfortably inserted into the vagina. The delivery vehicle can be prepared in a variety of geometries. For example, the delivery vehicle can be shaped as a tear drop, a cone with frustoconical ends, a cylinder, a cylinder with larger “cap” portion, or in any other shape suitable for, and that eases insertion into, the vagina. In certain embodiments, the delivery vehicle can be used in connection with an applicator. In other embodiments, the delivery vehicle can be digitally inserted.

With reference to FIG. 2, delivery vehicle 200 includes pharmaceutical composition 202 and capsule 204. Width 208 represents the thickness of capsule 204, for example about 0.108 inches. The distance from one end of delivery vehicle 200 to another is represented by distance 206, for example about 0.690 inches. The size of delivery vehicle 200 can also be described by the arc swept by a radius of a given length. For example, arc 210, which is defined by the exterior of gelatin 204, is an arc swept by a radius of about 0.189 inches. Arc 212, which is defined by the interior of capsule 204, is an arc swept by a radius of about 0.0938 inches. Arc 214, which is defined by the exterior of gelatin 204 opposite arc 210, is an arc swept by a radius of about 0.108 inches. Suitable capsules of other dimensions can be provided. In certain embodiments, capsule 204 has dimensions the same as or similar to the ratios as provided above relative to each other. In some embodiments, the gelatin capsule can further comprise one or more components selected from the group consisting of hydrolyzed gelatin, sorbitol-sorbitan solution, water, glycerin, titanium dioxide, FD&C Red #40, ethanol, ethyl acetate, propylene glycol, polyvinyl acetate phthalate, isopropyl alcohol, polyethylene glycol, and ammonium hydroxide.

In certain embodiments, the delivery vehicle can be designed to remain in the vagina until the pharmaceutical composition is released. In certain embodiments, the delivery vehicle can dissolve intravaginally and can be absorbed into the vaginal tissue with the pharmaceutical composition, which can minimize vaginal discharge. In some embodiments, the delivery vehicle can be made from constituents that are nontoxic, for example, gelatin.

EXAMPLES

The pharmaceutical compositions described herein are now further detailed with reference to the following examples. These examples are provided for the purpose of illustration only and the embodiments described herein should in no way be construed as being limited to these examples. Rather, the embodiments should be construed to encompass any and all variations which become evident as a result of the teaching provided herein.

Example 1: Solubilizing Agents

Compositions having the ingredients shown in Table 1 were prepared by combining the ingredients using standard preparatory techniques.

TABLE 1 Estradiol Fill Formulas A B C Viscosity (cP) Composition/ 1418 semi-solid 37.5 Component % w/w % w/w % w/w Estradiol 0.008% w/w   0.008% w/w   0.008% w/w   Triacetin 90% w/w Kolliphor HS 15 90% w/w (Solutol HS 15) Lauroglycol 90 90% w/w Tefose 63 10% w/w 10% w/w Kolliphor RH40 10% w/w

Example 2: Pharmaceutical Composition

Estradiol was combined with one or more pharmaceutically acceptable solubilizing agents. The estradiol used in the pharmaceutical composition can be pharmaceutical grade, micronized estradiol, although other forms can also be used. The pharmaceutical composition included estradiol in a dosage strength of from about 1 μg to about 50 μg. The pharmaceutical composition can include 4 μg of estradiol. The pharmaceutical composition can include 10 μg of estradiol. The pharmaceutical composition can include 25 μg of estradiol.

The estradiol can be combined with pharmaceutically acceptable solubilizing agents as described herein, and, optionally, other excipients, to form a pharmaceutical composition.

Pharmaceutical compositions comprising one or more solubilizing agents as described herein that are liquid or semi-solid at room temperature can be tested using a Brookfield viscometer (Brookfield Engineering Laboratories, Middleboro, Mass.) at room temperature.

Pharmaceutical compositions comprising one or more solubilizing agents as described herein that are solid at room temperature can be assessed at 37° C. to determine their melting characteristics. The viscosity of the gels can be important during encapsulation of the formulation.

A dispersion assessment of the pharmaceutical compositions comprising one or more solubilizing agents as described herein can be performed. A dispersion assessment can be performed by transferring 300 mg of each vehicle system in 100 mL of 37° C. water, without agitation, and observing for mixing characteristics. Generally speaking, it is believed that formulations able to readily disperse in aqueous solution will have better dispersion characteristics upon administration.

Example 3: Delivery Vehicle

The pharmaceutical composition is delivered in a gelatin capsule delivery vehicle. The gelatin capsule delivery vehicle includes, for example, gelatin (e.g., Gelatin, NF (150 Bloom, Type B)), hydrolyzed collagen (e.g., GELITA, GELITA AG, Eberbach, Germany), glycerin, sorbitol special, or other excipients in proportions that are well known and understood by persons of ordinary skill in the art. Sorbitol special can be obtained commercially and can tend to act as a plasticizer and humectant.

A variety of delivery vehicles, Gels A through F, were developed, as shown in Table 4.

TABLE 2 Gelatin Capsule Delivery Vehicles A B C D E F Ingredient % w/w % w/w % w/w % w/w % w/w % w/w Gelatin, NF 41.0 41.0 41.0 41.0 43.0 43.0 (150 Bloom, Type B) Glycerin 99.7%, 6.0 6.0 6.0 6.0 18.0 18.0 USP Sorbitol Special, 15.0 15.0 15.0 15.0 — — USP GELITA 3 — — — 3.0 — (hydrolyzed collagen) Citric acid — 0.1 0.5 1 — 0.1 Purified Water 35.0 37.9 37.5 37.0 36.0 38.9 TOTAL 100.0 100.0 100.0 100.0 100.0 100.0 Dissolution gel 48 min 50 min 75 min 70 min — — strips, Avg. of (42, 45, (50, 51, (76, 75, (70, 71, 3 (500 mL, 58) 50) 74) 70) DH2O, 50 rpm @ 37° C.) Dissolution gel 70 min — — — 78 min 82 min strips, Avg. of 3 (500 mL, pH 4 buffer, 50 rpm @ 37° C.)

Each delivery vehicle A through F was prepared at a temperature range from about 45° C. to about 85° C. Each molten delivery vehicle A through F was cast into a film, dried, and cut into strips. The strips were cut into uniform pieces weighing about 0.5 g, with about 0.5 mm thickness. Strips were placed into a USP Type 2 dissolution vessel in either water or pH 4 buffer solution and the time for them to completely dissolve was recorded (see Table 4). Delivery vehicle A had the fastest dissolution in both water and pH 4 buffer solution.

Example 4: Pharmaceutical Compositions with Delivery Vehicle

Various combinations of the pharmaceutical compositions comprising one or more solubilizing agents described herein and delivery vehicles of Table 4 can be prepared.

An aliquot of about 300 mg to about 310 mg of a pharmaceutical composition comprising one or more solubilizing agents as described herein can be prepared as described above. To encapsulate the vehicle system, each 300 mg to about 310 mg pharmaceutical composition aliquot can be encapsulated in about 200 mg of the gelatin capsule delivery vehicle. The aliquot size is arbitrary depending on the concentration of the estradiol and the desired gelatin capsule delivery vehicle size. Artisans will readily understand how to adjust the amount of estradiol in the pharmaceutical composition to accommodate a given size of delivery vehicle, when the delivery vehicle encapsulates the pharmaceutical composition.

Example 5: Process Using One or More Solubilizing Agents of the Present Disclosure

FIG. 1 illustrates an embodiment of a method making a pharmaceutical composition comprising estradiol solubilized in a solubilizing agent comprising one or more solubilizing agents as described herein encapsulated in a soft gelatin delivery vehicle 100. In operation 102, the solubilizing agent(s) is heated to 40° C.±5° C. Heating can be accomplished through any suitable means. The heating can be performed in any suitable vessel, such as a stainless-steel vessel. Other pharmaceutical compositions can be made using the same general method by substituting various excipients, including the solubilizing agent.

In operation 104, GELUCIRE is mixed with the first solubilizing agent comprising to form the finished solubilizing agent. As used herein, any of the second solubilizing agents described herein can be used in operation 104 in place of GELUCIRE. Mixing is performed as would be known to persons of ordinary skill in the art, for example by impeller, agitator, stirrer, or other like devices used to mix pharmaceutical compositions. Operation 104 can be performed under an inert or relatively inert gas atmosphere, such as nitrogen gas. Mixing can be performed in any vessels that are known to persons of ordinary skill in the art, such as a stainless-steel vessel or a steel tank.

In operation 106 estradiol is mixed into the solubilizing agent. In embodiments, the estradiol is in a micronized form when mixed into the solubilizing agent. In other embodiments, the estradiol added is in a non-micronized form. Mixing can be facilitated by an impeller, agitator, stirrer, or other like devices used to mix pharmaceutical compositions. Operation 106 can be performed under an inert or relatively inert gas atmosphere, such as nitrogen gas.

In embodiments, however, the addition of estradiol can be performed prior to operation 104. In that regard, operations 104 and 106 are interchangeable with respect to timing or can be performed contemporaneously with each other.

In operation 110, the gelatin delivery vehicle is prepared. Any of the gelatin delivery vehicles described herein can be used in operation 110. In embodiments, gelatin, hydrolyzed collagen, glycerin, and other excipients are combined at a temperature range from about 45° C. to about 85° C. and prepared as a film. Mixing can occur in a steel tank or other container used for preparing gelatin delivery vehicles. Mixing can be facilitated by an impellor, agitator, stirrer, or other devices used to combine the contents of gelatin delivery vehicles. Operation 110 can be performed under an inert or relatively inert gas atmosphere, such as nitrogen gas. In embodiments, the gelatin delivery vehicle mixture is degassed prior to being used to encapsulate the pharmaceutical composition.

In operation 112, the gelatin delivery vehicle encapsulates the pharmaceutical composition, according to protocols well-known to persons of ordinary skill in the art. In operation 112, a soft gelatin capsule delivery vehicle is prepared by combining the pharmaceutical composition made in operation 106 with the gelatin delivery vehicle made in operation 110. The gelatin can be wrapped around the material, partially or fully encapsulating it or the gelatin can also be injected or otherwise filled with the pharmaceutical composition made in operation 106.

In embodiments, operation 112 is completed in a suitable die to provide a desired shape. Vaginal soft gel capsules can be prepared in a variety of geometries. For example, vaginal soft gel capsules can be shaped as a tear drop, a cone with frustoconical end, a cylinder, a cylinder with larger “cap” portion as illustrated in FIG. 2, or other shapes suitable for insertion into the vagina. The resulting pharmaceutical composition encapsulated in the soft gelatin delivery vehicle can be inserted digitally or with an applicator.

The breadth and scope of the present invention should not be limited by any of the above-described exemplary embodiments but should be defined only in accordance with the following claims and their equivalents.

All patents, patent applications, and other references noted or referenced in this application are hereby incorporated by reference in their entirety.

Claims

1. A vaginal insert comprising a therapeutically effective amount of estradiol; and a solubilizing agent, wherein the solubilizing agent comprises at least one C2-C5 fatty acid or a glycol ester, monoglyceride, diglyceride, or triglyceride thereof.

2. The vaginal insert of claim 1, wherein the therapeutically effective amount of estradiol is from about 1 microgram to about 25 micrograms.

3.-6. (canceled)

7. The vaginal insert of claim 1, further comprising a second solubilizing agent selected from the group consisting of a mixture of PEG-6 stearate, ethylene glycol palmitostearate, and PEG-32 stearate; a mixture of hard fat, glyceryl ricinoleate, ceteth-20, and steareth-20; polyoxyl 40 hydrogenated castor oil USP; hard fat polyoxyl 20 cetostearyl ether; and combinations thereof.

8. The vaginal insert of claim 7, wherein the second solubilizing agent is a mixture of PEG-6 stearate, ethylene glycol palmitostearate, and PEG-32 stearate.

9. The vaginal insert of claim 1, wherein the viscosity of the composition is about 5 cP to about 3000 cP at room temperature.

10. (canceled)

11. The vaginal insert of claim 1, wherein the insert further comprises a capsule encapsulating the therapeutically effective amount of estradiol and the solubilizing agent.

12. (canceled)

13. The vaginal insert of claim 1, wherein the solubilizing agent comprises at least one C3 fatty acid or a glycol mono- or di-ester thereof, a monoglyceride, diglyceride, or triglyceride thereof, or a combination of any of the foregoing.

14. A vaginal insert comprising:

(a) a therapeutically effective amount of estradiol;
(b) a first solubilizing agent comprising one or more polyethylene glycol mono- or di-esters of a hydroxy C16-C26 fatty acid; and
(c) a second solubilizing agent comprising a mixture of PEG-6 stearate, ethylene glycol palmitostearate, and PEG-32 stearate.

15. The vaginal insert of claim 14, wherein the therapeutically effective amount of estradiol is from about 1 microgram to about 25 micrograms.

16.-20. (canceled)

21. The vaginal insert of claim 14, wherein the insert further comprises a capsule encapsulating the estradiol, the first solubilizing agent, and the second solubilizing agent.

22. (canceled)

23. A vaginal insert comprising:

(d) a therapeutically effective amount of estradiol;
(e) a first solubilizing agent comprising propylene glycol monolaurate; and
(f) a second solubilizing agent comprising polyoxyl 40 hydrogenated castor oil USP.

24. The vaginal insert of claim 23, wherein the therapeutically effective amount of estradiol is from about 1 microgram to about 25 micrograms.

25.-28. (canceled)

29. The vaginal insert of claim 23, wherein the viscosity of the composition is about 5 cP to about 3000 cP at room temperature.

30. (canceled)

31. The vaginal insert of claim 23, wherein the insert further comprises a capsule encapsulating the estradiol, the first solubilizing agent, and the second solubilizing agent.

32. (canceled)

33. A method of treating an estrogen-deficient state, comprising administering to a female in need thereof, the vaginal insert of claim 1.

34. (canceled)

35. The method of claim 33, wherein the estrogen-deficient state is selected from the group consisting of vulvovaginal atrophy, dysuria, dyspareunia, estrogen-deficient urinary state, and vaginal bleeding associated with sexual activity.

36. (canceled)

37. A method of treating an estrogen-deficient state, comprising administering to a female in need thereof, the vaginal insert of claim 14.

38. (canceled)

39. The method of claim 37, wherein the estrogen-deficient state is selected from the group consisting of vulvovaginal atrophy, dysuria, dyspareunia, estrogen-deficient urinary state, and vaginal bleeding associated with sexual activity.

40. (canceled)

41. A method of treating an estrogen-deficient state, comprising administering to a female in need thereof, the vaginal insert of claim 23.

42. (canceled)

43. The method of claim 41, wherein the estrogen-deficient state is selected from the group consisting of vulvovaginal atrophy, dysuria, dyspareunia, estrogen-deficient urinary state, and vaginal bleeding associated with sexual activity.

44. (canceled)

Patent History
Publication number: 20230277555
Type: Application
Filed: Mar 1, 2023
Publication Date: Sep 7, 2023
Inventors: Veeran Gowda KADAJJI (Princeton, NJ), Mafruhul BARI (Boca Raton, FL), Annette SHADIACK (Somerset, NJ), Thorsteinn THORSTEINSSON (Boynton Beach, FL), Peter H.R. PERSICANER (Boca Raton, FL)
Application Number: 18/115,983
Classifications
International Classification: A61K 31/565 (20060101); A61K 9/00 (20060101); A61K 9/48 (20060101);